<DOC>
	<DOCNO>NCT00414089</DOCNO>
	<brief_summary>The purpose study see well Zevalin work treatment low grade indolent B-cell lymphoma give patient previous treatment lymphoma otherwise would follow `` watch &amp; wait '' policy .</brief_summary>
	<brief_title>Efficacy Safety Treatment With Single Dose 90Y-ibritumomab Tiuxetan Patients With Low Tumor Burden Untreated Indolent NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>histologically confirm indolent lymphoma include : follicular grade 1 2 small lymphocytic marginal zone ( nodal ) marginal zone ( splenic ) mucosa associate lymphoid tissue ( MALT ) evidence transformation Stage III IV disease No prior therapy involvement le 25 % bone marrow assessment trephine biopsy absolute lymphocyte count ≤ x 109/L platelet ≥ 150 x 109/L hemoglobin ≥ 100g/L absolute neutrophil count ≥ 1.5 x 109/L least one bidimensionally measurable lesion least 2cm CT scan anticancer treatment NHL prior radiation therapy prior myeloablative therapy ( bone marrow peripheral blood stem cell transplant ) malignancy within past 10 year except adequately treat nonmelanoma skin tumor carcinoma situ cervix presence central nervous system lymphoma patient know HIV positive patient know seropositivity Hepatitis C virus , Hepatitis B virus active infection uncontrolled treatment patient abnormal liver function : total bilirubin &gt; 1.5X ULN ALT &gt; 2.5X ULN patient abnormal renal function : serum creatinine &gt; 2.5X ULN know hypersensitivity murine antibody proteins immunotherapy precede 6 month ( include monoclonal antibody , interleukin , interferon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>